Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer

In 2009 a prospective, randomized Phase II trial (NCT00842998) was initiated to evaluate the activity of HER2‐targeting agents without chemotherapy (CT) in HER2‐positive metastatic breast cancer (MBC) patients. The primary tumors of the patients enrolled in this study offered a unique opportunity to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Montemurro, Filippo, Prat, Aleix, Rossi, Valentina, Valabrega, Giorgio, Sperinde, Jeff, Peraldo-Neia, Caterina, Donadio, Michela, Galván, Patricia, Sapino, Anna, Aglietta, Massimo, Baselga, José, Scaltriti, Maurizio
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2013
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528507/
https://ncbi.nlm.nih.gov/pubmed/24075779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.08.013
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados